Schizoaffective Disorders Completed Phase 4 Trials for Quetiapine (DB01224)

Also known as: Schizoaffective disorder / Schizophrenia schizoaffective / Schizoaffective psychosis / Schizo-affective type schizophrenia

IndicationStatusPhase
DBCOND0033299 (Schizoaffective Disorders)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02307396Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic PatientsTreatment
NCT00156715Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use DisorderOther
NCT00330863Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating EfficacyTreatment
NCT00061802Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective DisorderTreatment
NCT00090012Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective DisorderTreatment
NCT00206102A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective DisorderTreatment
NCT00208143Seroquel Therapy for Substance Use Disorders Comorbid With SchizophreniaTreatment
NCT00423878Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective DisorderTreatment
NCT00515723Glucose and Lipid Metabolism on Antipsychotic MedicationTreatment